Anzhelika Vorobyeva
Anzhelika Vorobyeva
Verified email at igp.uu.se
Title
Cited by
Cited by
Year
Development of a bioluminescent nitroreductase probe for preclinical imaging
AG Vorobyeva, M Stanton, A Godinat, KB Lund, GG Karateev, KP Francis, ...
PLoS One 10 (6), 2015
392015
Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors
A Vorobyeva, O Bragina, M Altai, B Mitran, A Orlova, A Shulga, ...
Contrast Media & Molecular Imaging 2018, 2018
372018
Optimal composition and position of histidine-containing tags improves biodistribution of 99m Tc-labeled DARPin G3
A Vorobyeva, A Schulga, E Konovalova, R Güler, J Löfblom, M Sandström, ...
Scientific reports 9 (1), 1-11, 2019
292019
Cyclic versus Noncyclic Chelating Scaffold for 89Zr-Labeled ZEGFR:2377 Affibody Bioconjugates Targeting Epidermal Growth Factor Receptor Overexpression
D Summer, J Garousi, M Oroujeni, B Mitran, KG Andersson, A Vorobyeva, ...
Molecular pharmaceutics 15 (1), 175-185, 2018
252018
Comparative Evaluation of Two DARPin Variants: Effect of Affinity, Size, and Label on Tumor Targeting Properties
S Deyev, A Vorobyeva, A Schulga, G Proshkina, R Güler, J Löfblom, ...
Molecular pharmaceutics 16 (3), 995-1008, 2019
222019
Indirect Radioiodination of DARPin G3 Using N-succinimidyl-Para-Iodobenzoate Improves the Contrast of HER2 Molecular Imaging
A Vorobyeva, A Schulga, SS Rinne, T Günther, A Orlova, S Deyev, ...
International Journal of Molecular Sciences 20 (12), 3047, 2019
192019
Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono-and Bi-Valent Anti-HER3 Affibody Therapeutic Constructs
M Altai, C Leitao, S Rinne, A Vorobyeva, C Atterby, S Ståhl, V Tolmachev, ...
Cells 7 (10), 164, 2018
162018
Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-terminus with indium-111 or technetium-99m
J Garousi, S Lindbo, B Mitran, J Buijs, A Vorobyeva, A Orlova, ...
Scientific reports 7 (1), 1-11, 2017
162017
Site-specific conjugation of recognition tags to trastuzumab for peptide nucleic acid-mediated radionuclide HER2 pretargeting
K Westerlund, A Vorobyeva, B Mitran, A Orlova, V Tolmachev, ...
Biomaterials 203, 73-85, 2019
142019
Comparison of tumor‑targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2
A Vorobyeva, A Sсhulga, E Konovalova, R Güler, B Mitran, J Garousi, ...
International Journal of Oncology 54 (4), 1209-1220, 2019
142019
Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER2-expressing tumours
J Garousi, S Lindbo, J Borin, E von Witting, A Vorobyeva, M Oroujeni, ...
European Journal of Pharmaceutics and Biopharmaceutics 134, 37-48, 2019
142019
Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1
SM Deyev, A Vorobyeva, A Schulga, A Abouzayed, T Günther, J Garousi, ...
International Journal of Biological Macromolecules 145, 216-225, 2020
132020
Trastuzumab cotreatment improves survival of mice with PC‐3 prostate cancer xenografts treated with the GRPR antagonist 177Lu‐DOTAGA‐PEG2‐RM26
B Mitran, SS Rinne, MW Konijnenberg, T Maina, BA Nock, M Altai, ...
International journal of cancer 145 (12), 3347-3358, 2019
132019
Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of 68Ga-Labeled Tracers
C Dahlsson Leitao, SS Rinne, B Mitran, A Vorobyeva, KG Andersson, ...
International journal of molecular sciences 20 (5), 1080, 2019
132019
Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of 68Ga-Labeled Tracers
C Dahlsson Leitao, SS Rinne, B Mitran, A Vorobyeva, KG Andersson, ...
International journal of molecular sciences 20 (5), 1080, 2019
132019
Influence of composition of cysteine-containing peptide-based chelators on biodistribution of 99mTc-labeled anti-EGFR affibody molecules
M Oroujeni, KG Andersson, X Steinhardt, M Altai, A Orlova, B Mitran, ...
Amino acids 50 (8), 981-994, 2018
122018
Optimized Molecular Design of ADAPT-Based HER2-Imaging Probes Labeled with 111In and 68Ga
S Lindbo, J Garousi, B Mitran, A Vorobyeva, M Oroujeni, A Orlova, ...
Molecular pharmaceutics 15 (7), 2674-2683, 2018
122018
Selection of the optimal macrocyclic chelators for labeling with 111In and 68Ga improves contrast of HER2 imaging using engineered scaffold protein ADAPT6.
J Garousi, S Lindbo, A Vorobyeva, M Altai, M Oroujeni, B Mitran, A Orlova, ...
European journal of pharmaceutics and biopharmaceutics: official journal of …, 2019
92019
Selection of the optimal macrocyclic chelators for labeling with 111In and 68Ga improves contrast of HER2 imaging using engineered scaffold protein ADAPT6
E von Witting, J Garousi, S Lindbo, A Vorobyeva, M Altai, M Oroujeni, ...
European Journal of Pharmaceutics and Biopharmaceutics 140, 109-120, 2019
92019
Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy
A Vorobyeva, K Westerlund, B Mitran, M Altai, S Rinne, J Sörensen, ...
Scientific reports 8 (1), 1-10, 2018
92018
The system can't perform the operation now. Try again later.
Articles 1–20